Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Issue 3 (20th May 2019)

• Record Type: Journal Article
• Authors: Yu, Jacky K.; Iorio, Alfonso; Edginton, Andrea N.
• Other Names: Ahuja Sanjay investigator.; Álvarez Román Ma Teresa investigator.; Arrieta Ma E. investigator.; Arola Mikko investigator.; Barillari Giovanni investigator.; Balasa Vinod investigator.; Belletrutti Mark investigator.; Berrueco Moreno Ruben investigator.; Beurrier Philippe investigator.; Bidlingmaier Cristoph investigator.; Blanchette Victor investigator.; Blatny Jan investigator.; Bonanad Santiago investigator.; Brose Kelsey investigator.; Brown Deborah investigator.; Byant Paulette C. investigator.; Canaro Mariana investigator.; Carvalho Manuela investigator.; Catarino Cristina investigator.; Chitlur Meera investigator.; Cockrell Erin investigator.; Chowdary Pratima investigator.; Cnossen Marjon investigator.; Collins Peter investigator.; Coppens Michial investigator.; Croteau Stacy investigator.; Cultrera Dorina investigator.; de Cristofaro Raimundo investigator.; de Raucourt Emmauelle investigator.; Desprez Dominique investigator.; Dunn Amy investigator.; El‐Ekiabi Magda investigator.; Faganel Kotnik Barbara investigator.; Fischer Kathleen investigator.; Frotscher Brigit investigator.; Garbiero Susana investigator.; Garrido Ruiz Raquel investigator.; Gill Joan investigator.; Gomez del Castillo Carmen investigator.; Gottstein Saskia investigator.; Lassandro Giuseppe investigator.; Giordano Paola investigator.; Hart Daniel investigator.; Hegemann Inga investigator.; Hermans Cedric investigator.; Hua Baolai investigator.; Hwang Nina investigator.; Jackson Shannon investigator.; James Paula investigator.; Katsarou Olga investigator.; Kavakli Kaan investigator.; Kempton Christine investigator.; Kentouche Karim investigator.; Khan Osman investigator.; Kobelt Rainer investigator.; Kruse‐Jarres Rebecca investigator.; Laane Edward investigator.; Larson Eric investigator.; Lassila Riitta investigator.; Lee Adrienne investigator.; Poon Man‐Chiu investigator.; Lissick Jennifer investigator.; Langstrom Satu investigator.; Mahlangu Johnny investigator.; Makris Michael investigator.; Marchesini Emmanuela investigator.; Mateo Jose investigator.; Marco Vera Pacual investigator.; Martorell Marta investigator.; Matsushita Tadashi investigator.; McCrae Simon investigator.; Mignot‐Castellano Eva investigator.; Montcrieff Caitlin investigator.; Maes Philip investigator.; Mondelars Veerle investigator.; Bekart Marlies investigator.; Mora Elena investigator.; Cristóbal Morales Juan investigator.; Mourey Guillaume investigator.; Bertrand Marie Ann investigator.; Napolitano Mariasanta investigator.; Siragusa Sergio investigator.; Negrier Claude investigator.; Neme Daniela investigator.; Niinimaki Ritta investigator.; Oldenburg Johannes investigator.; Albert Thilo investigator.; Ornstein Deborah investigator.; Ozelo Margarete investigator.; Panetta John Carl investigator.; Neufeld Ellis J. investigator.; P'Ng Stephanie investigator.; Peerlinck Kathelijne investigator.; Pollio Berardino investigator.; Pouplard Claire investigator.; Gruel Yves investigator.; Prezotti Alessandra investigator.; Price Vicky investigator.; Primacakti Fitri investigator.; Puyade Mathieu investigator.; Radossi Paolo investigator.; Raffini Leslie investigator.; Ragni Margaret investigator.; Rangarajan Savita investigator.; Reding Mark T. investigator.; Reid Robin investigator.; Restrepo Jose investigator.; Ramirez Jose investigator.; Recht Michael investigator.; Rodriguez Lopez Manuel investigator.; Ruiz‐Sàez Arlette investigator.; Saleh Mahasen investigator.; Shapiro Amy investigator.; Sharathkumar Anjali investigator.; Selmeczi Anna investigator.; Simpson Mindy investigator.; Singleton Tami investigator.; Cruz Maria Sol investigator.; Soto Veronica investigator.; Steele MacGregor investigator.; Streif Werner investigator.; Sun Hao Wei investigator.; Ritchie Bruce investigator.; Sun Jing investigator.; Feng Xiaqin investigator.; Suzuki Takashi investigator.; Nagao Asuza investigator.; Takemoto Cliff investigator.; Tapp Heather investigator.; Teitel Jerry investigator.; Tinmouth Alan investigator.; Thornburg Courtney investigator.; Tosseto Alberto investigator.; Turnstall Oliver investigator.; Vezina Catherine investigator.; Warren Beth investigator.; Wheeler Allison investigator.; Wilches Gutierrez Juan D. investigator.; Wu John K.M. investigator.; Wynn Tung investigator.; Yang Renchi investigator.; Young Guy investigator.; Zanon Ezio investigator.; Zupan Irena investigator.;
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 3:Issue 3(2019)
• Page Start: 528
• Page End: 541
• Publication Date: 2019-05-20
• Subjects: drug substitution -- factor IX -- factor VIII -- hemophilia A -- hemophilia B; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12204
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhibitor development studies. Research on how best to switch concentrates with respect to dosing regimen are lacking, and currently a trial‐and‐error approach is used for dosing the new factor concentrate. In the future, studies looking at the predictability of pharmacokinetics (PK) of a new factor concentrate based on individual PK knowledge of the original factor concentrate may offer clinical benefit by providing a safer switching approach and protocol.